Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lubo Isakovic"'
Autor:
Stephen William Claridge, Arkadii Vaisburg, Claire Bonfils, Jeffrey M. Besterman, Stephane Raeppel, James Wang, Marielle Fournel, Helene Sainte-Croix, Lubo Isakovic, Normand Beaulieu, Oscar Mario Saavedra, Franck Raeppel, Michael Mannion, Christiane R. Maroun
Publikováno v:
Cancer Research. 73:930-930
Despite breakthroughs in the clinical development of tyrosine kinase inhibitors, challenges remain in overcoming resistance to these molecular targeted therapies. Advances in our understanding of mechanisms of resistance to targeted agents will impro
Autor:
Marielle Fournel, Marja Dubay, Christian Lemoyne, Stephen William Claridge, Arkadii Vaisburg, Michael Mannion, Robert E. Martell, Lubo Isakovic, Oscar Mario Saavedra, Franck Raeppel, Claire Bonfils, Normand Beaulieu, Hélène Ste-Croix, Carole Beaulieu, Stephane Raeppel, Jeffrey M. Besterman, James Wang, Isabelle Dupont, Christiane R. Maroun
Publikováno v:
Cancer Research. 70:3612-3612
MGCD265 is an oral multitargeted receptor tyrosine kinase inhibitor in Phase II clinical development. MGCD265 targets the Met receptor tyrosine kinase and blocks Met activities which contribute to cancer development and progression such as cell proli
Autor:
Isabelle Dupont, Claire Bonfils, Christiane R. Maroun, Arkadii Vaisburg, Lubo Isakovic, Stephen William Claridge, Jeffrey M. Besterman, Marja Dubay, Stephane Raeppel, Hélène Ste-Croix, Normand Beaulieu, Franck Raeppel, Oscar Mario Saavedra, Michael Mannion
Publikováno v:
Cancer Research. 70:3609-3609
MGCD265 is a multitargeted receptor tyrosine kinase inhibitor in Phase II clinical development, which inhibits the activation of regulators of cancer development and progression by targeting Met, the three members of the VEGFR family, Tie-2 and Ron.